Hemolytic anemia cost-effectiveness of therapy

Authors: Shyam Patel [1]

Hemolytic anemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hemolytic anemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT Scan
MRI Scan
Echocardiography or Ultrasound
Imaging Findings
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hemolytic anemia cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hemolytic anemia cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hemolytic anemia cost-effectiveness of therapy
CDC on Hemolytic anemia cost-effectiveness of therapy
Hemolytic anemia cost-effectiveness of therapy in the news
Blogs on Hemolytic anemia cost-effectiveness of therapy
Directions to Hospitals Treating Hemolytic anemia
Risk calculators and risk factors for Hemolytic anemia cost-effectiveness of therapy

The most cost-effective intervention for workup of hemolytic anemia is labs including a complete blood count and physican exam.

The most cost-effective intervention for therapy of hemolytic anemia is corticosteroids. Alternative immunosuppressive agents like cyclosporine or azathioprine are more costly and should only be used if corticosteroids are ineffective or cannot be tolerated.